IMPORTANT: You must read the following disclaimer before continuing.
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. VIEWING THIS INFORMATION MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS. PLEASE NOTE THAT THE DISCLAIMER SET OUT BELOW MAY BE ALTERED OR UPDATED. YOU SHOULD READ IT IN FULL EACH TIME YOU VISIT THE WEBSITE. BY ACCESSING THIS INFORMATION ON THIS WEBSITE, YOU AGREE TO THE TERMS AND CONDITIONS BELOW, INCLUDING ANY MODIFICATIONS THAT MAY BE MADE TO THEM FROM TIME TO TIME.
THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA AND ARE INTENDED FOR DISTRIBUTION TO, AND USE BY, RESIDENTS OF INDIA ONLY.
THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY WOCKHARDT LIMITED (THE 'COMPANY') SOLELY TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ('SEBI ICDR REGULATIONS') AND THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED ('COMPANIES ACT').
MAKING THE PRELIMINARY PLACEMENT DOCUMENT DATED MARCH 20, 2024 (THE 'PRELIMINARY PLACEMENT DOCUMENT') AVAILABLE IN ELECTRONIC FORMAT ON THIS WEBSITE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY EQUITY SHARES OF THE COMPANY ('EQUITY SHARES') IN THE PROPOSED QUALIFIED INSTITUTIONS PLACEMENT ('ISSUE') IN ANY JURISDICTION.
THIS DISCLAIMER APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THE FOLLOWING DISCLAIMER APPLIES TO THE PRELIMINARY PLACEMENT DOCUMENT IN RELATION TO THE ISSUE OF THE COMPANY FILED WITH BSE LIMITED AND THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED (TOGETHER, THE 'STOCK EXCHANGES'). YOU ARE ADVISED TO READ THIS DISCLAIMER CAREFULLY BEFORE READING, ACCESSING OR MAKING ANY OTHER USE OF THE PRELIMINARY PLACEMENT DOCUMENT.
THE EQUITY SHARES OFFERED IN THE ISSUE HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE 'U.S. SECURITIES ACT'), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES EXCEPT PURSUANT TO A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. THE EQUITY SHARES OFFERED IN THE ISSUE ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN 'OFFSHORE TRANSACTIONS' AS DEFINED IN AND IN RELIANCE ON REGULATIONS UNDER THE U.S. SECURITIES ACT.
THE PRELIMINARY PLACEMENT DOCUMENT HAS NOT BEEN AND WILL NOT BE FILED AS A PROSPECTUS OR A STATEMENT IN LIEU OF A PROSPECTUS WITH ANY REGISTRAR OF COMPANIES IN INDIA UNDER THE COMPANIES ACT. THE PRELIMINARY PLACEMENT DOCUMENT HAS BEEN FILED AS A PRIVATE PLACEMENT OFFER LETTER WITH THE STOCK EXCHANGES. THE PRELIMINARY PLACEMENT DOCUMENT IS EXCLUSIVE TO THE RECIPIENT AND IS NOT INTENDED AND DOES NOT CONSTITUTE AN OFFER OR A SOLICITATION OR INVITATION OF AN OFFER TO SUBSCRIBE TO THE SECURITIES DESCRIBED IN THE PRELIMINARY PLACEMENT DOCUMENT TO THE GENERAL PUBLIC OR ANY PERSON OR CLASS OF INVESTORS OTHER THAN ELIGIBLE QUALIFIED INSTITUTIONAL BUYERS, AS DEFINED IN THE SEBI ICDR REGULATIONS. THE PRELIMINARY PLACEMENT DOCUMENT HAS NOT BEEN REVIEWED AND APPROVED BY ANY REGULATORY AUTHORITY IN INDIA OR ABROAD, INCLUDING THE SECURITIES AND EXCHANGE BOARD OF INDIA, THE RESERVE BANK OF INDIA, ANY REGISTRAR OF COMPANIES IN INDIA OR ANY STOCK EXCHANGE IN INDIA. THE PRELIMINARY PLACEMENT DOCUMENT IS NOT AND SHOULD NOT BE CONSTRUED AS AN INVITATION, OFFER OR SALE OF ANY SECURITIES TO THE PUBLIC IN INDIA.
NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER (AS DEFINED IN THE PRELIMINARY PLACEMENT DOCUMENT) AND ANY OF THEIR RESPECTIVE AFFILIATES, ACCEPTS ANY LIABILITY WHATSOEVER, DIRECT OR INDIRECT, THAT MAY ARISE FROM THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE. ACCESS TO THIS WEBSITE OR THE PRELIMINARY PLACEMENT DOCUMENT DOES NOT CONSTITUTE A RECOMMENDATION BY THE COMPANY, THE BOOK RUNNING LEAD MANAGER, ANY OF THEIR RESPECTIVE AFFILIATES OR ANY OTHER PARTY TO SUBSCRIBE TO OR BUY OR SELL THE EQUITY SHARES OFFERED IN THE ISSUE.
THE PRELIMINARY PLACEMENT DOCUMENT WILL NOT BE CIRCULATED OR DISTRIBUTED TO THE PUBLIC IN INDIA OR ANY OTHER JURISDICTION, AND WILL NOT CONSTITUTE A PUBLIC OFFER IN INDIA OR ANY OTHER JURISDICTION.
THE INFORMATION IN THE PRELIMINARY PLACEMENT DOCUMENT IS AS OF THE DATE THEREOF AND NEITHER THE COMPANY, ITS DIRECTORS NOR THE BOOK RUNNING LEAD MANAGER ARE UNDER ANY OBLIGATION TO UPDATE OR REVISE THE PRELIMINARY PLACEMENT DOCUMENT TO REFLECT CIRCUMSTANCES ARISING AFTER THE DATE THEREOF.
THE ISSUE, AND THE DISTRIBUTION OF THE PRELIMINARY PLACEMENT DOCUMENT IS BEING MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED UNDER THE SEBI ICDR REGULATIONS ('QIBs') WHICH ARE NOT RESTRICTED FROM PARTICIPATING IN THE ISSUE UNDER THE APPLICABLE LAWS, INCLUDING THE SEBI ICDR REGULATIONS, ARE ELIGIBLE TO INVEST IN THIS ISSUE ('ELIGIBLE QIBs') IN RELIANCE UPON CHAPTER VI OF THE SEBI ICDR REGULATIONS AND SECTIONS 42 AND 62, AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT. UNLESS A SERIALLY NUMBERED PRELIMINARY PLACEMENT DOCUMENT ACCOMPANIED BY AN APPLICATION FORM IS ADDRESSED TO A SPECIFIC QIB INVITING SUCH QIB TO MAKE A BID THROUGH SUCH APPLICATION FORM, NO OFFER AND/OR INVITATION OF OFFER SHALL BE DEEMED TO HAVE BEEN MADE.
YOU ARE ACCESSING THIS WEBSITE AT YOUR OWN RISK AND IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT IT IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE. NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER OR ANY OF THEIR RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS OR EMPLOYEES WILL BE LIABLE OR HAVE ANY RESPONSIBILITY OF ANY KIND FOR ANY LOSS OR DAMAGE THAT YOU INCUR IN THE EVENT OF ANY FAILURE OR DISRUPTION OF THIS WEBSITE, OR RESULTING FROM THE ACT OR OMISSION OF ANY OTHER PARTY INVOLVED IN MAKING THIS WEBSITE OR THE DATA CONTAINED THEREIN AVAILABLE TO YOU, OR FROM ANY OTHER CAUSE RELATING TO YOUR ACCESS TO, INABILITY TO ACCESS, OR USE OF THE WEBSITE OR THESE MATERIALS. IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT IT IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE.
THE PRELIMINARY PLACEMENT DOCUMENT MAY NOT BE DISTRIBUTED IN WHOLE OR IN PART, TO ANY OTHER PERSON. FAILURE TO COMPLY WITH THIS DISCLAIMER MAY RESULT IN A VIOLATION OF THE APPLICABLE LAWS.
If you are not in India, please exit this webpage.
By clicking on the “I Confirm” button below you represent to the Company and the Book Running Lead Manager that:
If you cannot make these confirmations, you must press the button marked 'I Do Not Confirm'.
IMPORTANT: You must read the following disclaimer before continuing.
PLEASE READ THIS NOTICE CAREFULLY. IT APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. VIEWING THIS INFORMATION MAY NOT BE LAWFUL IN CERTAIN JURISDICTIONS. PLEASE NOTE THAT THE DISCLAIMER SET OUT BELOW MAY BE ALTERED OR UPDATED. YOU SHOULD READ IT IN FULL EACH TIME YOU VISIT THE WEBSITE. BY ACCESSING THIS INFORMATION ON THIS WEBSITE, YOU AGREE TO THE TERMS AND CONDITIONS BELOW, INCLUDING ANY MODIFICATIONS THAT MAY BE MADE TO THEM FROM TIME TO TIME.
THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA AND ARE INTENDED FOR DISTRIBUTION TO, AND USE BY, RESIDENTS OF INDIA ONLY.
THESE MATERIALS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY WOCKHARDT LIMITED (THE 'COMPANY') SOLELY TO COMPLY WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (THE 'SEBI ICDR REGULATIONS') AND THE COMPANIES ACT, 2013 AND THE RULES MADE THEREUNDER, EACH AS AMENDED (THE 'COMPANIES ACT').
MAKING THE PLACEMENT DOCUMENT DATED 26 MARCH, 2024 (THE 'PLACEMENT DOCUMENT') AVAILABLE IN ELECTRONIC FORMAT ON THIS WEBSITE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE EQUITY SHARES OF THE COMPANY ('EQUITY SHARES') IN THE QUALIFIED INSTITUTIONS PLACEMENT (THE 'ISSUE') IN ANY JURISDICTION.
THIS DISCLAIMER APPLIES TO ALL PERSONS WHO VIEW THIS WEBSITE. THE FOLLOWING DISCLAIMER APPLIES TO THE PLACEMENT DOCUMENT IN RELATION TO THE ISSUE OF THE COMPANY FILED WITH BSE LIMITED AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED (TOGETHER, THE 'STOCK EXCHANGES'). YOU ARE ADVISED TO READ THIS DISCLAIMER CAREFULLY BEFORE READING, ACCESSING OR MAKING ANY OTHER USE OF THE PLACEMENT DOCUMENT.
THE EQUITY SHARES OFFERED IN THE ISSUE HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE 'U.S. SECURITIES ACT'), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES EXCEPT PURSUANT TO A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. THE EQUITY SHARES OFFERED IN THE ISSUE ARE BEING OFFERED AND SOLD ONLY OUTSIDE THE UNITED STATES IN 'OFFSHORE TRANSACTIONS' AS DEFINED IN AND IN RELIANCE ON REGULATIONS UNDER THE U.S. SECURITIES ACT.
THE PLACEMENT DOCUMENT HAS NOT BEEN AND WILL NOT BE FILED AS A PROSPECTUS OR A STATEMENT IN LIEU OF A PROSPECTUS WITH ANY REGISTRAR OF COMPANIES IN INDIA UNDER THE COMPANIES ACT. THE PLACEMENT DOCUMENT HAS BEEN FILED AS A PRIVATE PLACEMENT OFFER LETTER WITH THE STOCK EXCHANGES. THE PLACEMENT DOCUMENT IS EXCLUSIVE TO THE RECIPIENT AND IS NOT INTENDED AND DOES NOT CONSTITUTE AN OFFER OR A SOLICITATION OR INVITATION OF AN OFFER TO SUBSCRIBE TO THE SECURITIES DESCRIBED IN THE PLACEMENT DOCUMENT TO THE GENERAL PUBLIC OR ANY PERSON OR CLASS OF INVESTORS OTHER THAN ELIGIBLE QUALIFIED INSTITUTIONAL BUYERS, AS DEFINED IN THE SEBI ICDR REGULATIONS. THE PLACEMENT DOCUMENT HAS NOT BEEN REVIEWED AND APPROVED BY ANY REGULATORY AUTHORITY IN INDIA OR ABROAD, INCLUDING THE SECURITIES AND EXCHANGE BOARD OF INDIA, THE RESERVE BANK OF INDIA, ANY REGISTRAR OF COMPANIES IN INDIA OR ANY STOCK EXCHANGE IN INDIA. THE PLACEMENT DOCUMENT IS NOT AND SHOULD NOT BE CONSTRUED AS AN INVITATION, OFFER OR SALE OF ANY SECURITIES TO THE PUBLIC IN INDIA.
NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER (AS DEFINED IN THE PLACEMENT DOCUMENT) AND ANY OF THEIR RESPECTIVE AFFILIATES, ACCEPTS ANY LIABILITY WHATSOEVER, DIRECT OR INDIRECT, THAT MAY ARISE FROM THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE. ACCESS TO THIS WEBSITE OR THE PLACEMENT DOCUMENT DOES NOT CONSTITUTE A RECOMMENDATION BY THE COMPANY, THE BOOK RUNNING LEAD MANAGER, ANY OF THEIR RESPECTIVE AFFILIATES OR ANY OTHER PARTY TO SUBSCRIBE TO OR BUY OR SELL THE EQUITY SHARES OFFERED IN THE ISSUE.
THE PLACEMENT DOCUMENT WILL NOT BE CIRCULATED OR DISTRIBUTED TO THE PUBLIC IN INDIA OR ANY OTHER JURISDICTION, AND WILL NOT CONSTITUTE A PUBLIC OFFER IN INDIA OR ANY OTHER JURISDICTION.
THE INFORMATION IN THE PLACEMENT DOCUMENT IS AS OF THE DATE THEREOF AND NEITHER THE COMPANY, ITS DIRECTORS NOR THE BOOK RUNNING LEAD MANAGER ARE UNDER ANY OBLIGATION TO UPDATE OR REVISE THE PLACEMENT DOCUMENT TO REFLECT CIRCUMSTANCES ARISING AFTER THE DATE THEREOF.
THE ISSUE, AND THE DISTRIBUTION OF THE PLACEMENT DOCUMENT IS BEING MADE TO QUALIFIED INSTITUTIONAL BUYERS AS DEFINED UNDER THE SEBI ICDR REGULATIONS ('QIBs') WHICH ARE NOT RESTRICTED FROM PARTICIPATING IN THE ISSUE UNDER THE APPLICABLE LAWS, INCLUDING IN RELIANCE UPON CHAPTER VI OF THE SEBI ICDR REGULATIONS AND SECTIONS 42 AND 62, AND OTHER APPLICABLE PROVISIONS OF THE COMPANIES ACT.
YOU ARE ACCESSING THIS WEBSITE AT YOUR OWN RISK AND IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT IT IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE. NONE OF THE COMPANY, THE BOOK RUNNING LEAD MANAGER OR ANY OF THEIR RESPECTIVE AFFILIATES, DIRECTORS, OFFICERS OR EMPLOYEES WILL BE LIABLE OR HAVE ANY RESPONSIBILITY OF ANY KIND FOR ANY LOSS OR DAMAGE THAT YOU INCUR IN THE EVENT OF ANY FAILURE OR DISRUPTION OF THIS WEBSITE, OR RESULTING FROM THE ACT OR OMISSION OF ANY OTHER PARTY INVOLVED IN MAKING THIS WEBSITE OR THE DATA CONTAINED THEREIN AND MADE AVAILABLE TO YOU, OR FROM ANY OTHER CAUSE RELATING TO YOUR ACCESS TO, INABILITY TO ACCESS, OR USE OF THE WEBSITE OR THESE MATERIALS. IT IS YOUR RESPONSIBILITY TO TAKE PRECAUTIONS TO ENSURE THAT YOUR ACCESS TO THIS WEBSITE AND THE MATERIALS CONTAINED THEREIN IS FREE FROM VIRUSES AND OTHER ITEMS OF A DESTRUCTIVE NATURE.
THE PLACEMENT DOCUMENT MAY NOT BE DISTRIBUTED IN WHOLE OR IN PART, TO ANY OTHER PERSON. FAILURE TO COMPLY WITH THIS DISCLAIMER MAY RESULT IN A VIOLATION OF THE APPLICABLE LAWS.
If you are not in India, please exit this webpage.
By clicking on the 'I Confirm' button below you represent to the Company and the Book Running Lead Manager that:
If you cannot make these confirmations, you must press the button marked 'I Do Not Confirm'.
| Product name<\/th>\n | Pack Description<\/th>\n | Strength<\/th>\n | Composition<\/th>\n | Therapy<\/th>\n | Formulations<\/th>\n<\/tr>\n<\/thead>\n |
|---|---|---|---|---|---|
| Spasgan tab<\/td>\n | 6 tablets per Alum\/PVC blister. 1 blister with instruction for use per plastic pack. 10 plastic packs per cardboard pack.\n\n10 tablets per Alum\/PVC blister. 2 blisters with instruction for use per cardboard pack. 10 blisters with an equal number of instructions per cardboard pack.<\/td>\n | Metamizole sodium monohydrate 500.0 mg+ pitofenone hydrochloride 5.0 mg+fenpiverinium bromide 0.1 mg<\/td>\n | Metamizole sodium monohydrate 500.0 mg, pitofenone hydrochloride 5.0 mg, fenpiverinium bromide 0.1 mg, lactose monohydrate, povidone K-30, magnesium stearate, colloidal silicon dioxide<\/td>\n | Non-narcotic analgesic and antispasmodic agent<\/td>\n | Metamizole sodium monohydrate 500.0 mg, pitofenone hydrochloride 5.0 mg, fenpiverinium bromide 0.1 mg, lactose monohydrate, povidone K-30, magnesium stearate, colloidal silicon dioxide<\/td>\n<\/tr>\n |
| Spasgan NEO<\/td>\n | 1) 10 tablets in PVC\/PVDC\/aluminum blister. 2 blisters with instruc-tion for use in a cardboard box.\n\n2) 10 tablets in PVC\/PVDC\/aluminum blister. 10 blisters with an equal number of Instructions for use in a carton pack.\n\n3) 6 tablets in PVC\/PVDC\/aluminum blister. 1 blister with instruction for use in plastic packaging.\n\n4) 6 tablets in PVC\/PVDC\/aluminum blister. 1 blister with instruction for use in plastic packaging. 6 plastic packings in a carton pack.<\/td>\n | Ibuprofen 400.0 mg +pitofenone hydrochloride 5.0 mg+fenpiverinium bromide 0,1 mg<\/td>\n | Ibuprofen 400.0 mg, pitofenone hydrochloride 5.0 mg, fenpiverinium bromide 0,1 mg excipients (Maize Starch 88.0 mg, Microcrystalline Cellulose 85.9 mg, Sodium starch glycolate (type A) 14.7 mg, Alginic Acid 10.6 mg, Disodium Edetate Dihydrate 0.6 mg, Povidone (PVP K-90) 11.0 mg, Colloidal Silica (Aerosil 200) 7.0 mg, Croscarmellose sodium 4.7 mg, Sodium Lauryl Sulfate 2.4 mg, Magnesium Stearate 5.0 mg, Talc 5.0 mg, coating [Opadry II 85G68918 white (polyvinyl alcohol, 7.4 mg, titanium dioxide 5.76 mg, talc, 3.36 mg, macrogol 2.1 mg, soybean lecithin 0.58 mg) 19.2 mg]<\/td>\n | Combined analgesic antispasmodic.<\/td>\n | Ibuprofen 400.0 mg +pitofenone hydrochloride 5.0 mg+fenpiverinium bromide 0,1 mg<\/td>\n<\/tr>\n |
| Spasgan inj<\/td>\n | 5.0 ml in a glass ampoule for breaking off white on a plastic tray.\n\n1 or 5 pallets together with a carton box.<\/td>\n | Metamizole sodium 500 mg, pitofenone hydrochloride 2 mg, fenpiverinium bromide 0.02 mg<\/td>\n | Metamizole sodium 500 mg, pitofenone hydrochloride 2 mg, fenpiverinium bromide 0.02 mg, water for injection up to 1 ml<\/td>\n | Analgesic non-narcotic and antispasmodic agent.<\/td>\n | Metamizole sodium 500 mg, pitofenone hydrochloride 2 mg, fenpiverinium bromide 0.02 mg, water for injection up to 1 ml<\/td>\n<\/tr>\n |
| Wozulim-N<\/td>\n | human insulin (recombinant) 100 IU\/ml:\ncartridge 3 ml, No. 1, No. 5 in a carton pack;\nsyringe pen Dispopen with a cartridge of 3 ml No. 1, No. 5 in a carton pack;\nbottle 10 ml No. 1 in a carton pack<\/td>\n | human insulin (recombinant) suspension for subcutaneous administration 100 IU\/ml (3.5 mg)<\/td>\n | recombinant human insulin 100 IU (3.5 mg), excipients (glycerol, anhydrous sodium phosphate, metacresol, phenol, protamine sulfate, sodium hydroxide, zinc oxide, hydrochloric acid, water for injection- up to 1 ml<\/td>\n | Hypoglycemic agent, intermediate-acting insulin.<\/td>\n | recombinant human insulin 100 IU (3.5 mg), excipients (glycerol, anhydrous sodium phosphate, metacresol, phenol, protamine sulfate, sodium hydroxide, zinc oxide, hydrochloric acid, water for injection)<\/td>\n<\/tr>\n |
| Wozulim-R<\/td>\n | Human insulin (recombinant) 100 IU\/ml:\ncartridge 3 ml, No. 1, No. 5 in a carton pack;\nsyringe pen Dispopen with a cartridge of 3 ml No. 1, No. 5 in a carton pack;\nbottle 10 ml No. 1 in a carton pack<\/td>\n | Human insulin (recombinant) 100 IU\/ml injection (3.5 mg)<\/td>\n | Human insulin (recombinant) – 100 IU (3.5 mg);\nGlycerol – 16.32 mg, metacresol – 2.50 mg, sodium hydroxide – 0.40 mg, sodium citrate dihydrate – 0.19 mg, zinc oxide – 0.031 mg, citric acid monohydrate – 0.0021 mg, hydrochloric acid – 0.001 ml, water for injection – up to 1 ml.<\/td>\n | Hypoglycemic agent – short-acting insulin<\/td>\n | Human insulin (recombinant) – 100 IU (3.5 mg);\nGlycerol – 16.32 mg, metacresol – 2.50 mg, sodium hydroxide – 0.40 mg, sodium citrate dihydrate – 0.19 mg, zinc oxide – 0.031 mg, citric acid monohydrate – 0.0021 mg, hydrochloric acid – 0.001 ml, water for injection – up to 1 ml.<\/td>\n<\/tr>\n |
| Wozulim-30\/70<\/td>\n | Human insulin (recombinant) 100 IU\/ml:\ncartridge 3 ml, No. 1, No. 5 in a carton pack;\nsyringe pen Dispopen with a cartridge of 3 ml No. 1, No. 5 in a carton pack;\nbottle 10 ml No. 1 in a carton pack<\/td>\n | Human insulin (recombinant) suspension for subcutaneous administration 100 IU\/ml (4.0 mg)<\/td>\n | Human insulin (genetically engineered) – 100 IU (4.0 mg);\nprotamine sulfate – 0.28 mg, zinc oxide – 0.032 mg, metacresol – 1.60 mg, phenol – 0.65 mg, glycerol – 16.32 mg, sodium hydroxide – 0.40 mg, disubstituted anhydrous sodium phosphate – 2, 08 mg, hydrochloric acid – 0.00072 ml, water for injection – up to 1 ml.<\/td>\n | A hypoglycemic agent is a combination of short-acting and intermediate-acting insulins.<\/td>\n | Human insulin (genetically engineered) – 100 IU (4.0 mg);\nprotamine sulfate – 0.28 mg, zinc oxide – 0.032 mg, metacresol – 1.60 mg, phenol – 0.65 mg, glycerol – 16.32 mg, sodium hydroxide – 0.40 mg, disubstituted anhydrous sodium phosphate – 2, 08 mg, hydrochloric acid – 0.00072 ml, water for injection – up to 1 ml.<\/td>\n<\/tr>\n |
| Spasgel<\/td>\n | Gel for external use 2.5%.\n30 g, 50 g and 100 g in an aluminum tube. The tube, along with instructions for use, is placed in a carton box.<\/td>\n | Gel for external use 2.5%<\/td>\n | Ketoprofen – 2.5 g.\ncarbomer 940 (carbopol 980), methyl parahydroxybenzoate, trometamol, lavender oil, polyester PE 240, ethanol (ethyl alcohol) 95%, purified water.<\/td>\n | Non-steroidal anti-inflammatory drugs for topical use.<\/td>\n | Ketoprofen – 2.5 g.\ncarbomer 940 (carbopol 980), methyl parahydroxybenzoate, trometamol, lavender oil, polyester PE 240, ethanol (ethyl alcohol) 95%, purified water.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":" Russia – CIS Product name Pack Description Strength Composition Therapy Formulations Spasgan tab 6 tablets per Alum\/PVC blister. 1 blister with instruction for use per plastic pack. 10 plastic packs per cardboard pack. 10 tablets per Alum\/PVC blister. 2 blisters with instruction for use per cardboard pack. 10 blisters with an equal number of instructions … <\/p>\n |